China's TopRidge Pharma to produce Sputnik V vaccine, Russia's RDIF says
The fund, which markets Sputnik V globally, said the two sides planned to cooperate on clinical trials in China and to promote its use there
The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement. Photo: Reuters
China's TopRidge Pharma has agreed to produce more than 100 million doses of Russia's two-shot Sputnik V vaccine against Covid-19, Russia's RDIF sovereign wealth fund said on Thursday.
The fund, which markets Sputnik V globally, said the two sides planned to cooperate on clinical trials in China and to promote its use there.
TopRidge Pharma will be able to distribute the vaccine in mainland China, Hong Kong, Macau and Taiwan, RDIF said in a statement.
Keep updated, follow The Business Standard's Google news channel
